company background image
301333 logo

R&G PharmaStudies SZSE:301333 Stock Report

Last Price

CN¥45.90

Market Cap

CN¥4.4b

7D

-8.4%

1Y

-29.4%

Updated

26 Apr, 2024

Data

Company Financials +

R&G PharmaStudies Co., Ltd.

SZSE:301333 Stock Report

Market Cap: CN¥4.4b

301333 Stock Overview

R&G PharmaStudies Co., Ltd. provides clinical research outsourcing services for pharmaceutical and medical device companies, and scientific research institutions in China.

301333 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance5/6
Financial Health5/6
Dividends0/6

R&G PharmaStudies Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for R&G PharmaStudies
Historical stock prices
Current Share PriceCN¥45.90
52 Week HighCN¥81.38
52 Week LowCN¥37.19
Beta0
1 Month Change-3.95%
3 Month Change-9.20%
1 Year Change-29.38%
3 Year Changen/a
5 Year Changen/a
Change since IPO-18.41%

Recent News & Updates

Recent updates

Shareholder Returns

301333CN Life SciencesCN Market
7D-8.4%4.9%2.1%
1Y-29.4%-37.8%-14.2%

Return vs Industry: 301333 exceeded the CN Life Sciences industry which returned -39% over the past year.

Return vs Market: 301333 underperformed the CN Market which returned -14.6% over the past year.

Price Volatility

Is 301333's price volatile compared to industry and market?
301333 volatility
301333 Average Weekly Movement9.8%
Life Sciences Industry Average Movement9.6%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 301333's share price has been volatile over the past 3 months.

Volatility Over Time: 301333's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,926David Wuwww.rg-pharma.com

R&G PharmaStudies Co., Ltd. provides clinical research outsourcing services for pharmaceutical and medical device companies, and scientific research institutions in China. It offers clinical trial consulting, clinical trial operation, data management and statistical analysis, technical services and solutions, biostatistical quantitative scientific support, and various services related to the clinical trial data monitoring committee, including participating in the committee or relevant statistical analysis for the committee. The company also provides clinical pharmacology services; biological sample testing services to analyze and detect the biological samples collected during the clinical trial, and to determine the concentration of the original drug and/or metabolites; and clinical trial site management services.

R&G PharmaStudies Co., Ltd. Fundamentals Summary

How do R&G PharmaStudies's earnings and revenue compare to its market cap?
301333 fundamental statistics
Market capCN¥4.41b
Earnings (TTM)CN¥156.79m
Revenue (TTM)CN¥737.77m

28.1x

P/E Ratio

6.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
301333 income statement (TTM)
RevenueCN¥737.77m
Cost of RevenueCN¥442.25m
Gross ProfitCN¥295.52m
Other ExpensesCN¥138.73m
EarningsCN¥156.79m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.63
Gross Margin40.06%
Net Profit Margin21.25%
Debt/Equity Ratio0.4%

How did 301333 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

11%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.